Highest-materiality recent filing
Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance
Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
FDA agrees to remove ANA screening, reclassify lupus risk for Dianthus' claseprubart trials
FDA agreed to remove anti-nuclear antibodies (ANAs) as screening criteria for all ongoing and future claseprubart trials.
Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants
Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.
Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results
Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26
Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.
Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones
Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).
Dianthus raises ~$270M in public offering of common stock and pre-funded warrants
Issued 6,487,879 common shares at $33.00/share and 1,112,121 pre-funded warrants at $32.999/share.
Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints
Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.
Dianthus Q1 net loss $29.5M; gMG trial enrollment complete, top-line Sep 2025
Net loss $29.5M ($0.82/sh) vs $13.7M ($0.54/sh) Q1 2024; cash $331.5M, runway into 2H'27.
Dianthus Therapeutics Q3 net loss $25.2M; cash $342.6M; Phase 3 CIDP trial planned by YE 2024
Net loss $25.2M ($0.74/sh) vs $14.8M ($3.78/sh) in Q3 2023; R&D expense rose to $25.5M from $8.0M.
Dianthus reports Q2 net loss $17.6M; cash $360.7M funds pipeline into 2H'27
Net loss $17.6M ($0.51/share) vs $11.1M ($12.73/share) in Q2 2023.
Dianthus shareholders approve 2.93M share increase to stock option plan
Stockholders approved an amendment increasing shares reserved under the stock option plan by 2,931,820 shares.
Dianthus reports FY2023 net loss $43.6M, cash $389M; Phase 2 gMG trial initiated
FY2023 net loss $43.6M ($8.45/share), R&D $32.8M, G&A $18.2M.
Dianthus Therapeutics raises $230M in PIPE financing at $12.00/share
PIPE gross proceeds ~$230M from 14.5M common shares at $12.00 and 4.7M pre-funded warrants at $11.999.
Dianthus expects ~$173M cash at year-end 2023; to present at JPM conference
Preliminary unaudited cash, equivalents, and short-term investments of ~$173M as of Dec 31, 2023.
Dianthus reports Q3 net loss $14.8M; positive Phase 1 data for DNTH103, cash $189.9M
Net loss of $14.8M ($3.78 per share); R&D expenses $8.0M, G&A $8.7M including $4.0M severance.
Dianthus files OpCo historical financials; pro forma cash runway into Q2 2026
OpCo net losses: $18.2M (H1 2023), $28.5M (FY2022), $13.1M (FY2021).
Reverse merger closed: Magenta becomes Dianthus Therapeutics; ticker changes to DNTH
Merger closed: Magenta combined with Dianthus OpCo; new entity trades as DNTH; ~14.8M shares post-merger.
Magenta Therapeutics stockholders approve merger with Dianthus; closing expected Sept 11
Stockholders approved share issuance and change of control (30.1M For, 6.3M Against) and reverse stock split (47.4M For).
Magenta to merge with Dianthus in reverse merger; Dianthus holders to own 78.7% of combined firm
Dianthus stockholders will own ~78.7% of combined company; Magenta holders ~21.3%.
Magenta Therapeutics pays $14.8M to terminate Cambridge sublease with Novartis
One-time termination payment of $14,780,188 to Novartis for early exit from 69,000 sq ft sublease.
Magenta Therapeutics adopts one-year stockholder rights plan to support strategic review
Rights plan triggers at 10% beneficial ownership; each right entitles holder to purchase preferred stock units at $3.75.
Magenta Therapeutics to cut ~84% of workforce, CEO Gardner departs; CFO Mahoney becomes President
Board approved restructuring plan reducing workforce by up to 56 positions (~84%), substantially complete by Feb 17, 2023.
Magenta Therapeutics halts all programs, explores strategic alternatives
Halts all development programs; will explore strategic alternatives including acquisition, merger, or business combination.
Magenta pauses MGTA-117 Phase 1/2 trial after participant death possibly related to drug
Latest participant dosed at Cohort 3 level (0.08 mg/kg) experienced Grade 5 SAE: respiratory failure and cardiac arrest leading to death.
Magenta stops MGTA-117 Cohort 4 dosing after two DLTs; to continue at Cohort 3
Three participants dosed in Cohort 4 (0.13 mg/kg); two had dose-limiting toxicities (respiratory SAEs).
Magenta reports MGTA-117 Phase 1/2 data: no DLTs, two patients became transplant eligible
MGTA-117 showed dose-dependent binding and depletion of CD117+ cells; no dose-limiting toxicities observed in 15 patients across Cohorts 1-3.
Magenta Therapeutics Q3 net loss $16.1M; cash $128.3M funds into Q2 2024
Cash, equivalents and marketable securities $128.3M at Sept 30, 2022, down from $176.9M at Dec 31, 2021.
Magenta Q2 net loss $17.3M; cash $139.4M; MGTA-117 interim data expected Q4 2022
Cash, equivalents, and marketable securities $139.4M as of June 30, 2022; funds operations into Q2 2024.
Magenta Q1 net loss $23M; MGTA-117 shows target binding and rapid clearance at lowest dose
Net loss of $23.0M for Q1 2022 vs. $17.5M in Q1 2021; R&D expenses rose to $16.5M from $11.7M.
Magenta Therapeutics prioritizes MGTA-117, cuts workforce 14%, extends cash runway into Q2 2024
MGTA-117 Phase 1/2 trial shows encouraging early data: well-tolerated with no significant adverse events, early pharmacodynamic signals.
Magenta Therapeutics reports Q4 2021 net loss $19.3M; first patient dosed in MGTA-117 trial
Cash, cash equivalents and marketable securities at Dec 31, 2021: $176.9M, expected to fund operations into Q4 2023.
On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.
On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.
On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.
On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.
On September 16, 2024, the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”) appointed Steven Romano, M.D. as a Class III director of the Company and as a member of the Science and Technology Committee of the Board (the “S&T Committee”), effective immediately.
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.
Jeffrey W. Albers, Bruce Booth, D. Phil., Thomas O. Daniel, M.D., Amy Lynn Ronneberg, David T. Scadden, M.D. and Michael Vasconcelles, M.D. resigned from the Board of Directors and committees of the Board of Directors on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.
Max materiality 1.00 · Median 0.62 · Most common event other_material